NeOnc NEO100 Phase 2a Results
Analysis based on 8 articles · First reported Aug 26, 2026 · Last updated Aug 28, 2026
The positive Phase 2a data and upcoming FDA interaction could boost investor confidence in NeOnc's pipeline, potentially supporting the stock price. However, clinical-stage risks and the need for further trials and regulatory approval temper the impact.
Neonci Technologies reported positive topline results from its NEO100-01 Phase 2a study in patients with recurrent or progressive Grade III and Grade IV IDH1-mutant glioma. The study met its primary endpoint with 48.9% six-month progression-free survival versus a prespecified 20% benchmark (p=0.0047), median overall survival of 26.09 months, and 86.7% of patients alive at six months. The company plans to request a Type B meeting with the United States — Food and Drug Administration to discuss a potential registrational pathway for NEO100. NeOnc also received UAE IND approvals for NEO100 and NEO212 in June, and insiders including CEO Amir Heshmatpour and director Thomas Chen have purchased shares. The company remains a clinical-stage biotechnology firm, and these results do not guarantee approval.
Set up alerts, explore entity relationships, search across thousands of events, and build custom intelligence feeds.
Open Dashboard